Heme Oxygenase-1 as a Target for TGF-β in Kidney Disease

Seminars in Nephrology

Volumn 32, Issue 3, 2012, Pages 277-286

  Zarjou, Abolfazl ^a   Agarwal, Anupam ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Fibrosis; Heme oxygenase 1; Kidney injury; Transforming growth factor

Indexed keywords

CYTOKINE; HEME OXYGENASE 1; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLOGICAL FUNCTIONS; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CHRONIC GRAFT REJECTION; DIABETIC NEPHROPATHY; ENZYME INDUCTION; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ACUTE KIDNEY INJURY; ANIMALS; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; GRAFT REJECTION; HEME OXYGENASE-1; HUMANS; KIDNEY; KIDNEY DISEASES; MICE; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84864147861     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.04.007     Document Type: Article

References (108)

1. Pohlers D., Brenmoehl J., Loffler I., Muller C.K., Leipner C., Schultze-Mosgau S., et al. TGF-beta and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 2009, 1792:746-756.
2. Cheng J., Grande J.P. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med (Maywood) 2002, 227:943-956.
3. Piek E., Heldin C.H., Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 1999, 13:2105-2124.
4. Hyytiainen M., Penttinen C., Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 2004, 41:233-264.
5. Saharinen J., Hyytiainen M., Taipale J., Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999, 10:99-117.
6. Barcellos-Hoff M.H. Latency and activation in the control of TGF-beta. J Mammary Gland Biol Neoplasia 1996, 1:353-363.
7. Moustakas A., Heldin C.H. The regulation of TGFbeta signal transduction. Development 2009, 136:3699-3714.
8. Sekelsky J.J., Newfeld S.J., Raftery L.A., Chartoff E.H., Gelbart W.M. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 1995, 139:1347-1358.
9. Savage C., Das P., Finelli A.L., Townsend S.R., Sun C.Y., Baird S.E., et al. Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components. Proc Natl Acad Sci U S A 1996, 93:790-794.
10. Wrighton K.H., Lin X., Feng X.H. Phospho-control of TGF-beta superfamily signaling. Cell Res 2009, 19:8-20.
11. Feng X.H., Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005, 21:659-693.
12. Hata A., Seoane J., Lagna G., Montalvo E., Hemmati-Brivanlou A., Massague J. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell 2000, 100:229-240.
13. Nagarajan R.P., Zhang J., Li W., Chen Y. Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem 1999, 274:33412-33418.
14. von Gersdorff G., Susztak K., Rezvani F., Bitzer M., Liang D., Bottinger E.P. Smad3 and Smad4 mediate transcriptional activation of the human Smad7 promoter by transforming growth factor beta. J Biol Chem 2000, 275:11320-11326.
15. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
16. Pelton R.W., Saxena B., Jones M., Moses H.L., Gold L.I. Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol 1991, 115:1091-1105.
17. Arteaga C.L., Dugger T.C., Hurd S.D. The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology. Breast Cancer Res Treat 1996, 38:49-56.
18. Verrecchia F., Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002, 118:211-215.
19. Dunker N., Krieglstein K. Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis. Eur J Biochem 2000, 267:6982-6988.
20. Kriegel M.A., Li M.O., Sanjabi S., Wan Y.Y., Flavell R.A. Transforming growth factor-beta: recent advances on its role in immune tolerance. Curr Rheumatol Rep 2006, 8:138-144.
21. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
22. Sanford L.P., Ormsby I., Gittenberger-de Groot A.C., Sariola H., Friedman R., Boivin G.P., et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997, 124:2659-2670.
23. Bartram U., Molin D.G., Wisse L.J., Mohamad A., Sanford L.P., Doetschman T., et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 2001, 103:2745-2752.
24. Kaartinen V., Voncken J.W., Shuler C., Warburton D., Bu D., Heisterkamp N., et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995, 11:415-421.
25. Kopp J.B., Factor V.M., Mozes M., Nagy P., Sanderson N., Bottinger E.P., et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996, 74:991-1003.
26. Shute J., Marshall L., Bodey K., Bush A. Growth factors in cystic fibrosis - when more is not enough. Paediatr Respir Rev 2003, 4:120-127.
27. Mirshafiey A., Mohsenzadegan M. TGF-beta as a promising option in the treatment of multiple sclerosis. Neuropharmacology 2009, 56:929-936.
28. Zhang H., Podojil J.R., Chang J., Luo X., Miller S.D. TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis. J Immunol 2010, 184:6629-6636.
29. Feagins L.A. Role of transforming growth factor-beta in inflammatory bowel disease and colitis-associated colon cancer. Inflamm Bowel Dis 2010, 16:1963-1968.
30. Rico M.C., Rough J.J., Del Carpio-Cano F.E., Kunapuli S.P., DeLa Cadena R.A. The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis. Curr Vasc Pharmacol 2010, 8:338-343.
31. Yagi K., Furuhashi M., Aoki H., Goto D., Kuwano H., Sugamura K., et al. c-myc is a downstream target of the Smad pathway. J Biol Chem 2002, 277:854-861.
32. Roberts A.B., Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003, 100:8621-8623.
33. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000, 97:8015-8020.
34. Ma L.J., Jha S., Ling H., Pozzi A., Ledbetter S., Fogo A.B. Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 2004, 65:106-115.
35. Ots M., Pechter U., Tamm A. Characteristics of progressive renal disease. Clin Chim Acta 2000, 297:29-41.
36. De Vecchi A.F., Dratwa M., Wiedemann M.E. Healthcare systems and end-stage renal disease (ESRD) therapies-an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999, 14(Suppl 6):31-41.
37. Bottinger E.P. TGF-beta in renal injury and disease. Semin Nephrol 2007, 27:309-320.
38. Yamamoto T., Noble N.A., Cohen A.H., Nast C.C., Hishida A., Gold L.I., et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996, 49:461-469.
39. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006, 69:213-217.
40. Gagliardini E., Benigni A. Therapeutic potential of TGF-beta inhibition in chronic renal failure. Expert Opin Biol Ther 2007, 7:293-304.
41. Hocevar B.A., Howe P.H. Analysis of TGF-beta-mediated synthesis of extracellular matrix components. Methods Mol Biol 2000, 142:55-65.
42. Yuan W., Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 2001, 276:38502-38510.
43. Gobe G.C., Axelsen R.A. Genesis of renal tubular atrophy in experimental hydronephrosis in the rat. Role of apoptosis. Lab Invest 1987, 56:273-281.
44. Kelly D.J., Cox A.J., Tolcos M., Cooper M.E., Wilkinson-Berka J.L., Gilbert R.E. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002, 61:31-39.
45. Miyajima A., Chen J., Lawrence C., Ledbetter S., Soslow R.A., Stern J., et al. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000, 58:2301-2313.
46. Trachtman H., Fervenza F.C., Gipson D.S., Heering P., Jayne D.R., Peters H., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011, 79:1236-1243.
47. Schiffer M., Bitzer M., Roberts I.S., Kopp J.B., ten Dijke P., Mundel P., et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807-816.
48. Choi M.E., Ballermann B.J. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. J Biol Chem 1995, 270:21144-21150.
49. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494.
50. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003, 63:464-473.
51. Rocco M.V., Chen Y., Goldfarb S., Ziyadeh F.N. Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 1992, 41:107-114.
52. Ziyadeh F.N., Sharma K., Ericksen M., Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994, 93:536-542.
53. Sharma K., Ziyadeh F.N., Alzahabi B., McGowan T.A., Kapoor S., Kurnik B.R., et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997, 46:854-859.
54. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42:450-456.
55. Isaka Y., Fujiwara Y., Ueda N., Kaneda Y., Kamada T., Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993, 92:2597-2601.
56. Sharma K., Jin Y., Guo J., Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45:522-530.
57. McGowan T.A., Dunn S.R., Falkner B., Sharma K. Stimulation of urinary TGF-beta and isoprostanes in response to hyperglycemia in humans. Clin J Am Soc Nephrol 2006, 1:263-268.
58. Hill-Kapturczak N., Chang S.H., Agarwal A. Heme oxygenase and the kidney. DNA Cell Biol 2002, 21:307-321.
59. Hill-Kapturczak N., Truong L., Thamilselvan V., Visner G.A., Nick H.S., Agarwal A. Smad7-dependent regulation of heme oxygenase-1 by transforming growth factor-beta in human renal epithelial cells. J Biol Chem 2000, 275:40904-40909.
60. Kutty R.K., Nagineni C.N., Kutty G., Hooks J.J., Chader G.J., Wiggert B. Increased expression of heme oxygenase-1 in human retinal pigment epithelial cells by transforming growth factor-beta. J Cell Physiol 1994, 159:371-378.
61. Hill-Kapturczak N., Jarmi T., Agarwal A. Growth factors and heme oxygenase-1: perspectives in physiology and pathophysiology. Antioxid Redox Signal 2007, 9:2197-2207.
62. Tracz M.J., Alam J., Nath K.A. Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol 2007, 18:414-420.
63. Agarwal A., Nick H.S. Renal response to tissue injury: lessons from heme oxygenase-1 GeneAblation and expression. J Am Soc Nephrol 2000, 11:965-973.
64. Jarmi T., Agarwal A. Heme oxygenase and renal disease. Curr Hypertens Rep 2009, 11:56-62.
65. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
66. Balla G., Jacob H.S., Balla J., Rosenberg M., Nath K., Apple F., et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 1992, 267:18148-18153.
67. Wang R. Resurgence of carbon monoxide: an endogenous gaseous vasorelaxing factor. Can J Physiol Pharmacol 1998, 76:1-15.
68. Dulak J., Deshane J., Jozkowicz A., Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008, 117:231-241.
69. Inguaggiato P., Gonzalez-Michaca L., Croatt A.J., Haggard J.J., Alam J., Nath K.A. Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. Kidney Int 2001, 60:2181-2191.
70. Nath K.A., Vercellotti G.M., Grande J.P., Miyoshi H., Paya C.V., Manivel J.C., et al. Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int 2001, 59:106-117.
71. Kapturczak M.H., Wasserfall C., Brusko T., Campbell-Thompson M., Ellis T.M., Atkinson M.A., et al. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am J Pathol 2004, 165:1045-1053.
72. Poss K.D., Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci U S A 1997, 94:10919-10924.
73. Yachie A., Niida Y., Wada T., Igarashi N., Kaneda H., Toma T., et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 1999, 103:129-135.
74. Radhakrishnan N., Yadav S.P., Sachdeva A., Pruthi P.K., Sawhney S., Piplani T., et al. Human heme oxygenase-1 deficiency presenting with hemolysis, nephritis, and asplenia. J Pediatr Hematol Oncol 2011, 33:74-78.
75. Ozaki K.S., Marques G.M., Nogueira E., Feitoza R.Q., Cenedeze M.A., Franco M.F., et al. Improved renal function after kidney transplantation is associated with heme oxygenase-1 polymorphism. Clin Transplant 2008, 22:609-616.
76. Exner M., Schillinger M., Minar E., Mlekusch W., Schlerka G., Haumer M., et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 2001, 8:433-440.
77. Lin C.C., Yang W.C., Lin S.J., Chen T.W., Lee W.S., Chang C.F., et al. Length polymorphism in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patients. Kidney Int 2006, 69:165-172.
78. Chin H.J., Cho H.J., Lee T.W., Na K.Y., Yoon H.J., Chae D.W., et al. The heme oxygenase-1 genotype is a risk factor to renal impairment of IgA nephropathy at diagnosis, which is a strong predictor of mortality. J Korean Med Sci 2009, 24(Suppl):S30-S37.
79. Fujita T., Toda K., Karimova A., Yan S.F., Naka Y., Yet S.F., et al. Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. Nat Med 2001, 7:598-604.
80. Gong L.M., Du J.B., Shi L., Shi Y., Tang C.S. Effects of endogenous carbon monoxide on collagen synthesis in pulmonary artery in rats under hypoxia. Life Sci 2004, 74:1225-1241.
81. Morse D. The role of heme oxygenase-1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2003, 29:S82-S86.
82. Li L., Grenard P., Nhieu J.T., Julien B., Mallat A., Habib A., et al. Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 2003, 125:460-469.
83. Wang H.D., Yamaya M., Okinaga S., Jia Y.X., Kamanaka M., Takahashi H., et al. Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. Am J Respir Crit Care Med 2002, 165:406-411.
84. Kie J.H., Kapturczak M.H., Traylor A., Agarwal A., Hill-Kapturczak N. Heme oxygenase-1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis. J Am Soc Nephrol 2008, 19:1681-1691.
85. Kim J.H., Yang J.I., Jung M.H., Hwa J.S., Kang K.R., Park D.J., et al. Heme oxygenase-1 protects rat kidney from ureteral obstruction via an antiapoptotic pathway. J Am Soc Nephrol 2006, 17:1373-1381.
86. Zeisberg M., Duffield J.S. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010, 21:1247-1253.
87. Kawada N., Moriyama T., Ando A., Fukunaga M., Miyata T., Kurokawa K., et al. Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction. Kidney Int 1999, 56:1004-1013.
88. Mark A., Hock T., Kapturczak M.H., Agarwal A., Hill-Kapturczak N. Induction of heme oxygenase-1 modulates the profibrotic effects of transforming growth factor-beta in human renal tubular epithelial cells. Cell Mol Biol 2005, 51:357-362.
89. Correa-Costa M., Semedo P., Monteiro A.P., Silva R.C., Pereira R.L., Goncalves G.M., et al. Induction of heme oxygenase-1 can halt and even reverse renal tubule-interstitial fibrosis. PLoS One 2010, 5:e14298.
90. Worou M.E., Belmokhtar K., Bonnet P., Vourc'h P., Machet M.C., Khamis G., et al. Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signaling. Cardiovasc Res 2011, 91:320-329.
91. Wang R.Q., Nan Y.M., Wu W.J., Kong L.B., Han F., Zhao S.X., et al. Induction of heme oxygenase-1 protects against nutritional fibrosing steatohepatitis in mice. Lipids Health Dis 2011, 10:31.
92. Duan Z.J., Yang D., Wang F., Sun Y.J., Sun X.Y., Zheng M.L. Heme oxygenase-1 regulates the major route involved in formation of immune hepatic fibrosis in rats. Chin Med J 2010, 123:3304-3308.
93. Suttner D.M., Dennery P.A. Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron. FASEB J 1999, 13:1800-1809.
94. Yet S.F., Tian R., Layne M.D., Wang Z.Y., Maemura K., Solovyeva M., et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 2001, 89:168-173.
95. Zhang J., Piantadosi C.A. Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J Clin Invest 1992, 90:1193-1199.
96. Shapiro S.M., Bhutani V.K., Johnson L. Hyperbilirubinemia and kernicterus. Clin Perinatol 2006, 33:387-410.
97. Kretschmer A., Moepert K., Dames S., Sternberger M., Kaufmann J., Klippel A. Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4. Oncogene 2003, 22:6748-6763.
98. Ning W., Song R., Li C., Park E., Mohsenin A., Choi A.M., et al. TGF-beta1 stimulates HO-1 via the p38 mitogen-activated protein kinase in A549 pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002, 283:L1094-L1102.
99. Chung S.W., Kwon M.Y., Kang Y.H., Chung H.T., Lee S.J., Kim H.P., et al. Transforming growth factor-beta1 suppression of endotoxin-induced heme oxygenase-1 in macrophages involves activation of Smad2 and downregulation of Ets-2. J Cell Physiol 2011, 227:351-360.
100. Pellacani A., Wiesel P., Sharma A., Foster L.C., Huggins G.S., Yet S.F., et al. Induction of heme oxygenase-1 during endotoxemia is downregulated by transforming growth factor-beta1. Circ Res 1998, 83:396-403.
101. Abdel-Aziz M.T., el-Asmar M.F., el-Miligy D., Atta H., Shaker O., Ghattas M.H., et al. Retrovirus-mediated human heme oxygenase-1 (HO-1) gene transfer into rat endothelial cells: the effect of HO-1 inducers on the expression of cytokines. Int J Biochem Cell Biol 2003, 35:324-332.
102. Terry C.M., Clikeman J.A., Hoidal J.R., Callahan K.S. TNF-alpha and IL-1alpha induce heme oxygenase-1 via protein kinase C, Ca2+, and phospholipase A2 in endothelial cells. Am J Physiol 1999, 276:H1493-H1501.
103. Agarwal A., Balla J., Balla G., Croatt A.J., Vercellotti G.M., Nath K.A. Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am J Physiol 1996, 271:F814-F823.
104. Hill-Kapturczak N., Sikorski E., Voakes C., Garcia J., Nick H.S., Agarwal A. An internal enhancer regulates heme- and cadmium-mediated induction of human heme oxygenase-1. Am J Physiol Renal Physiol 2003, 285:F515-F523.
105. Traylor A., Hock T., Hill-Kapturczak N. Specificity protein 1 and Smad-dependent regulation of human heme oxygenase-1 gene by transforming growth factor-beta1 in renal epithelial cells. Am J Physiol Renal Physiol 2007, 293:F885-F894.
106. Churchman A.T., Anwar A.A., Li F.Y., Sato H., Ishii T., Mann G.E., et al. Transforming growth factor-beta1 elicits Nrf2-mediated antioxidant responses in aortic smooth muscle cells. J Cell Mol Med 2009, 13:2282-2292.
107. Wakefield L.M., Roberts A.B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002, 12:22-29.
108. Doi K., Akaike T., Fujii S., Tanaka S., Ikebe N., Beppu T., et al. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer 1999, 80:1945-1954.